NCT01516307
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
Conditions: Metastatic Breast Cancer
Sponsors: Optimer Biotechnology, Inc.
Phase II
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
Conditions: Metastatic Breast Cancer
Sponsors: Optimer Biotechnology, Inc.
Phase II
Conditions: Lung Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)
Phase: n/a
Conditions: Fallopian Tubes, Ovarian Cancer, Peritoneal Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center
Phase I
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Sponsors: Gynecologic Oncology Group, National Cancer Institute (NCI)
Phase II
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Sponsors: Gynecologic Oncology Group, National Cancer Institute (NCI)
Phase III
Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer
Conditions: Prostate Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center
Phase II
Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence
Conditions: Breast Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)
Phase I
Vaccine Therapy Plus Biological Therapy in Treating Patients With Relapsed Prostate Cancer
Conditions: Prostate Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center
Phase II
Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer
Conditions: Prostate Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center
Phase I